Respiratorius AB Logo

Respiratorius AB

RESP | SPGR

Overview

Corporate Details

ISIN(s):
SE0004550192 (+2 more)
LEI:
5493001YRVZ5XYFEE615
Country:
Sweden
Address:
Scheeletorget 1, 223 81 Lund
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Respiratorius AB is a research-based pharmaceutical company focused on the development of innovative drug candidates. The company's primary focus is on oncology, specifically creating new treatments for aggressive forms of cancer such as diffuse large B-cell lymphoma (DLBCL). Its lead strategy involves developing a drug candidate intended as a pretreatment to enhance the efficacy of current standard therapies. Founded in 1999 as a spin-off from Lund University, Respiratorius leverages a team with extensive experience in clinical development, commercialization of research, and pharmaceutical business development. While historically involved in developing drugs for COPD and asthma, its current pipeline is centered on cancer.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Respiratorius AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Respiratorius AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Respiratorius AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-12-06 Johan Drott Other Buy 1,120 N/A

Peer Companies

Company Country Ticker View
VERICI DX PLC Logo
AI-powered diagnostic tests for the kidney transplant market, predicting organ rejection and injury.
United Kingdom VRCI
Vicore Pharma Holding Logo
Develops AT2 receptor drugs and a digital therapeutic for pulmonary fibrosis.
Sweden VICO
Vivoryon Therapeutics N.V. Logo
Develops small molecule therapies for severe age-related, inflammatory, and neurodegenerative diseases.
Germany VVY
R&D in renewable energy & manufacturing specialized tools for automotive & engineering.
Slovakia N/A
Xintela AB Logo
Develops stem cell therapies and targeted antibody treatments for cancer and osteoarthritis.
Sweden XINT
Xlife Sciences AG Logo
A life sciences incubator commercializing early-stage academic research for healthcare markets.
Switzerland XLS
XTL Biopharmaceuticals Ltd. Logo
Acquires and develops late-stage therapeutics for autoimmune diseases.
Israel XTLB
Yoshi Innovation Spolka Akcyjna Logo
A tech fund incubating MedTech, biotech, and defense ventures with investment and IP protection.
Poland YOS
Zealand Pharma Logo
Develops innovative peptide medicines for metabolic and rare diseases.
Denmark ZEAL
Ziccum AB Logo
Licenses drying tech for thermostable vaccines & biologics, eliminating the cold chain.
Sweden ZICC